New shot aims to boost platelets in bleeding disorder

NCT ID NCT07605845

Recruiting now Disease control Sponsor: Gliknik Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an injectable drug called GL-2045 in 42 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if GL-2045 can safely raise platelet counts like standard IVIg therapy but with fewer side effects. Participants receive repeated doses at different levels to find the best balance of safety and effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GL-2045
What this could lead to: If successful, this could offer a new treatment option for immune thrombocytopenia that works like IVIg but may be easier to take and have fewer side effects.
What could go wrong: This is an early Phase 1 trial with only 42 participants, so safety and effectiveness are not yet proven. The drug may not work as hoped or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA

Contacts and locations

Locations

Fortrea Clinical Research Unit Ltd
RECRUITING

Leeds, LS11 9EH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.